Demand persists regardless of policy preference
Concerns about Zyn going viral have sparked debate among health experts, parents and even politicians
As a proof-of-concept, a multiplexed assay was performed to detect both the EBOV and TMV OAS
On behalf of her new employer, she submitted a records request seeking internal documents from the agency showing how another company won approval for its e-cigarette products
With the orders, the nicotine pouches, which were authorized for sale in the United States since January 2025, can now be marketed with the following risk modification claim: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." Acting Director of the FDA's Center for Tobacco Products, Bret Koplow, Ph.D., J.D., said the modified risk product reviews are intended to "ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices." "Todays decision allows these products to be marketed with a modified risk claim that informs adults who smoke about the lower risks associated with these products," Koplow said
Click here to read more about the organizations efforts and successes